Vaccine Oka varicella-zoster virus genotypes are monomorphic in single vesicles and polymorphic in respiratory tract secretions

Journal of Infectious Diseases

Volumn 193, Issue 7, 2006, Pages 927-930

  Quinlivan, Mark A ^a   Gershon, Anne A ^c   Nichols, Richard A ^b   La Russa, Philip ^c   Steinberg, Sharon P ^c   Breuer, Judy ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE;

ADOLESCENT; ARTICLE; CASE REPORT; GENETIC HETEROGENEITY; GENOTYPE; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNIZATION; MALE; MEMBRANE VESICLE; MOLECULAR CLONING; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHIC LOCUS; PRIORITY JOURNAL; RESPIRATORY SYSTEM; VARICELLA ZOSTER VIRUS; VIRUS VIRULENCE;

CHICKENPOX; CHICKENPOX VACCINE; DNA, VIRAL; HERPESVIRUS 3, HUMAN; HUMANS; INFANT; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RESPIRATORY SYSTEM; SEQUENCE ANALYSIS, DNA; VACCINATION;

EID: 33645358086     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/500835     Document Type: Article

References (14)

1. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996; 45:1-25.
2. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287:606-11.
3. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005; 352:450-8.
4. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000; 284:1271-9.
5. Gershon AA. Varicella vaccine: rare serious problems-but the benefits still outweigh the risks. J Infect Dis 2003; 188:945-7.
6. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000; 19:916-23.
7. LaRussa P, Lungu O, Hardy I, Gershon A, Steinberg SP, Silverstein S. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol 1992; 66:1016-20.
8. Loparev VN, Argaw T, Krause PR, Takayama M, Schmidt DS. Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J Clin Microbiol 2000; 38:3156-60.
9. Quinlivan ML, Gershon AA, Steinberg SP, Breuer J. Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus. J Infect Dis 2004; 190:793-6.
10. Westrop GD, Wareham KA, Evans DM, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol 1989; 63: 1338-44.
11. Gorni Y, Sunamachi H, Mori Y, Nagaike K, Takahashi M, Yamanishi K. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 2002; 76:11447-59.
12. Sauerbrei A, Rubtcova E, Wutzler P, Schmid DS, Loparev VN. Genetic profile of an Oka varicella vaccine virus variant isolated from an infant with zoster. J Clin Microbiol 2004; 42:5604-8.
13. Gomi Y, Imagawa T, Takahashi M, Yamanishi K. Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity. J Med Virol 2000; 61: 497-503.
14. Shiraki K, Yoshida Y, Asano Y, Yamanishi K, Takahashi M. Pathogenetic tropism of varicella-zoster virus to primary human hepatocytes and attenuating tropism of Oka varicella vaccine strain to neonatal dermal fibroblasts. J Infect Dis 2003; 188:1875-7.